Testing a new treatment for advanced prostate cancer resistant to hormone therapy

Plain-English translation of NCT06241846 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called YL201 to see if it can help treat metastatic castration-resistant prostate cancer — a type of advanced prostate cancer that has stopped responding to standard hormone therapy. Researchers want to find the best dose and understand how safe and effective this medication is for patients like you.

Men with advanced prostate cancer that no longer responds to hormone treatments have limited options and often need new therapies. This trial exists to find out whether this medication could offer a new way to slow or stop cancer growth in patients who have already tried other hormone-based treatments.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with prostate cancer that has spread to other parts of your body (metastatic disease)
your cancer has stopped responding to hormone therapy and at least one other advanced prostate cancer treatment
you have had castration therapy — either surgical removal of the testicles at least 3 months ago, or ongoing hormone injections to lower testosterone
you have scans (CT, MRI, or bone scan) from the past 4 weeks confirming your cancer has spread
you are willing to provide a tumor tissue sample for research testing

You likely don't qualify if…

you have received more than 2 previous chemotherapy treatments for your prostate cancer
you have a genetic BRCA1 or BRCA2 mutation and have not yet tried PARP inhibitor therapy (if available and tolerated)
you cannot or will not maintain hormone castration therapy throughout the study

What participation looks like

The study has two parts. In Part 1, about 60 participants will receive YL201 through an IV infusion every 3 weeks at different dose levels to find the safest and most effective dose. In Part 2, about 40 additional participants will receive the recommended dose determined from Part 1. Throughout the trial, you will have regular visits to receive your medication, have blood tests, imaging scans, and check-ups to monitor how well the treatment is working and watch for side effects.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(24 sites)

China

Anhui Provincial Hospital, Hefei, Anhui

The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui

Peking University First Hospital, Beijing, Beijing Municipality

Peking University Third Hospital, Beijing, Beijing Municipality

Hunan Cancer Hospital, Hunan, Changsha